New yellow fever vaccine shows promise in early human trial
NCT ID NCT02743455
First seen Feb 18, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This early-stage study tested a new yellow fever vaccine (MVA-BN-YF) in 92 healthy adults aged 18-45. The goal was to check if the vaccine is safe and triggers a strong immune response, with some groups receiving an extra ingredient (adjuvant) to boost effectiveness. Results will help decide if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
University of Iowa - Vaccine Research and Education Unit
Iowa City, Iowa, 52242-2600, United States
Conditions
Explore the condition pages connected to this study.